Evidence map›Paper›PMID 29227625›Full record

ArticleACS chemical neuroscience2018

Genetic Reduction or Negative Modulation of mGlu

Nicole M Fisher, Rocco G Gogliotti, Sheryl Anne D Vermudez, Branden J Stansley, P Jeffrey Conn, Colleen M Niswender

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGluNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  4. PathogenicThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  5. Synthesis and SAR of a series of mGluBioorganic & medicinal chemistry letters · 2020
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nicole M FisherDepartment of Pharmacology , Vanderbilt University , Nashville , Tennessee 37232 , United States.ORCID 0000-0001-6740-9618
Rocco G GogliottiDepartment of Pharmacology , Vanderbilt University , Nashville , Tennessee 37232 , United States.
Sheryl Anne D VermudezDepartment of Pharmacology , Vanderbilt University , Nashville , Tennessee 37232 , United States.
Branden J StansleyDepartment of Pharmacology , Vanderbilt University , Nashville , Tennessee 37232 , United States.
P Jeffrey ConnDepartment of Pharmacology , Vanderbilt University , Nashville , Tennessee 37232 , United States.
Colleen M NiswenderDepartment of Pharmacology , Vanderbilt University , Nashville , Tennessee 37232 , United States.
Vanderbilt University · US

Funding

TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
Vanderbilt/Meharry Initiative for Minority Student DvptR25GM062459 · NIGMS · VANDERBILT UNIVERSITY · PI VELEZ EDWARDS, DIGNA R · 2002 to 2020
$10.4M
Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1M
Program in NeurogenomicsT32MH065215 · NIMH · VANDERBILT UNIVERSITY · PI ROGER J COLBRAN · 2002 to 2026
$6.4M
Functions of Metabotropic Glutamate Receptor SubtypesR37NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2014 to 2020
$3.5M
Normalizing E:I imbalance in Rett Syndrome by Modulation of Late Response GenesK01MH112983 · NIMH · VANDERBILT UNIVERSITY · PI GOGLIOTTI, ROCCO GEORGE · 2017 to 2020
$543k
Metabotropic Glutamate Receptor Regulation in MeCP2-Related DisordersR21MH102548 · NIMH · VANDERBILT UNIVERSITY · PI NISWENDER, COLLEEN M · 2014 to 2015
$431k
The therapeutic potential of mGlu3 modulation in MeCP2-related disordersF32MH111124 · NIMH · VANDERBILT UNIVERSITY · PI STANSLEY, BRANDEN J · 2016 to 2017
$113k
Metabotropic Glutamate Receptor 7 as a Novel Therapeutic Target for MECP2 Duplication SyndromeF31MH113259 · NIMH · VANDERBILT UNIVERSITY · PI FISHER, NICOLE MARIE · 2017 to 2019
$88k
NICHD NIH HHS U54 HD083211NIGMS NIH HHS R25 GM062459NIGMS NIH HHS T32 GM007628NIMH NIH HHS F31 MH113259NIMH NIH HHS F32 MH111124NIMH NIH HHS K01 MH112983NIMH NIH HHS R21 MH102548NIMH NIH HHS T32 MH065215NINDS NIH HHS R37 NS031373
6 · The paper itself

Abstract

Rett syndrome and MECP2 Duplication syndrome are neurodevelopmental disorders attributed to loss-of-function mutations in, or duplication of, the gene encoding methyl-CpG-binding protein 2 (MeCP2), respectively. We recently reported decreased expression and function of the metabotropic glutamate receptor 7 (mGlu

Indexed as

Allosteric RegulationAnimalsAnxietyBenzoxazolesDisease Models, AnimalExcitatory Amino Acid AgonistsFearLearningMicePhenotypePhosphinic AcidsReceptors, Metabotropic GlutamateX-Linked Intellectual DisabilityADX71743BenzoxazolesExcitatory Amino Acid AgonistsLSP4-2022metabotropic glutamate receptor 7Phosphinic AcidsReceptors, Metabotropic GlutamateADX71743MeCP2MECP2 Duplication syndromemGlu7negative allosteric modulatorRett syndrome

Identifiers

PMID29227625
PMCPMC6002927
OpenAlexW2773483622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.